Moleculin Biotech Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, has entered into an agreement with Sterling Pharma USA LLC for U.S. production of WP1122 to support its expanded development efforts in preparation for submitting a request to the FDA for Investigational New Drug (IND) status for WP1122 for the potential treatment of COVID-19.   “In light of the added complexity surrounding drug production...